Nivolumab for treating advanced (unresectable or metastatic) melanoma

Equality Impact Assessment (Guidance development) (PDF 155 KB)

Final appraisal determination

Final appraisal determination document (PDF 355 KB)

Committee papers (PDF 7.64 MB)

Final scope (PDF 121 KB)

Final matrix (PDF 101 KB)

NICE response to comments on the draft scope and provisional matrix (PDF 198 KB)

Draft scope for consultation (pre-referral) - March 2015 (PDF 124 KB)

Provisional matrix (pre-referral) - March 2015 (PDF 103 KB)

Melanoma (advanced, unresectable, metastatic) - nivolumab [ID846], [ID847], [ID848]: draft scope for consultation (pre-referral) - March 2015 (PDF 133 KB)

Equality impact assessment form (PDF 119 KB)